ArticleMolecular medicine reports2026
<p>Collagen III regulates the termination of liver regeneration by suppressing hepatocyte proliferation and promoting functional recovery</p>.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Termination of liver regeneration is important for restoring hepatic function after partial hepatectomy (PHx); however, its regulatory mechanisms remain poorly understood. The present study aimed to investigate the role of collagen III (col3) in terminating liver regeneration and its interaction with the β‑catenin signaling pathway. Initially, a 2/3 PHx mouse model was established, and col3 expression dynamics were examined via immunofluorescence and reverse transcription‑quantitative PCR. Collagenase III, also known as matrix metalloproteinase‑13, was used to degrade col3 during the termination phase of liver regeneration, and the resulting effects on hepatocyte proliferation, β‑catenin signaling and liver function were assessed. Methyl‑sulfonyl AB (MSAB), a β‑catenin inhibitor, was used to explore pathway involvement. The present study demonstrated that col3 expression in the parenchymal areas of the liver was decreased during the proliferation phase and increased during the termination phase. Collagenase‑induced col3 degradation enhanced hepatocyte proliferation, delayed regenerative termination, activated β‑catenin signaling, and impaired hepatocyte differentiation and liver function. Administration of MSAB rescued these effects, partially restoring termination and function. In conclusion, col3 may regulate the termination of liver regeneration by suppressing hepatocyte proliferation and promoting functional recovery. These findings provide new insights into collagen‑induced regulation of liver regeneration and potential therapeutic targets for optimizing hepatic recovery.</p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.